Skip to main content

Table 3 Characteristics of patients for transcriptome study

From: Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

Patient Gender Age, years Sokal score TKI first line, dosage Response to TKI
1 Male 36 Intermediate risk Imatinib, 400 mg Optimal response
2 Female 27 High risk Imatinib, 600 mg Optimal response
3 Female 57 Low risk Imatinib, 400 mg Optimal response
4 Female 55 Low risk Imatinib, 400 mg Optimal response
5 Female 68 Intermediate risk Imatinib, 400 mg Non-optimal response
6 Male 77 Low risk Imatinib, 400 mg Optimal response
7 Male 34 Intermediate risk Imatinib, 400 mg Non-optimal response
8 Male 20 Low risk Nilotinib, 600 mg Optimal response
9 Female 30 Low risk Imatinib, 400 mg Non-optimal response
10 Male 30 High risk Nilotinib, 800 mg Non-optimal response
11 Female 63 Intermediate risk Imatinib, 400 mg Non-optimal response
12 Female 38 Low risk Imatinib, 400 mg Optimal response
  1. TKI tyrosine kinase inhibitor